HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

The biology of erbB-2/nue/HER-2 and its role in cancer

1994 • 975 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1994 • 495 citations

ERBB2 oncogene in human breast cancer and its clinical significance

1998 • 457 citations

Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome

2000 • 444 citations

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1992 • 387 citations

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

2000 • 359 citations

The Molecular Pharmacology of SERMs

1999 • 307 citations

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

1999 • 300 citations

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

1998 • 270 citations

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

1997 • 196 citations

Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

1998 • 132 citations

Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation

1997 • 131 citations

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

2000 • 115 citations

Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer

2002 • 91 citations

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

1998 • 85 citations

P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy

1998 • 79 citations

Estrophilin assays in breast cancer: Quantitative features and application to the mastectomy specimen

1980 • 74 citations

New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry

1997 • 69 citations

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

1999 • 56 citations

Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.

2000 • 51 citations

Use of aromatase inhibitors in the adjuvant treatment of breast cancer.

1999 • 20 citations